Cargando…

Methods for the inclusion of real-world evidence in network meta-analysis

BACKGROUND: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, David A., Hussein, Humaira, Martina, Reynaldo, Dequen-O’Byrne, Pascale, Abrams, Keith R., Bujkiewicz, Sylwia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502389/
https://www.ncbi.nlm.nih.gov/pubmed/34627166
http://dx.doi.org/10.1186/s12874-021-01399-3
_version_ 1784580886826582016
author Jenkins, David A.
Hussein, Humaira
Martina, Reynaldo
Dequen-O’Byrne, Pascale
Abrams, Keith R.
Bujkiewicz, Sylwia
author_facet Jenkins, David A.
Hussein, Humaira
Martina, Reynaldo
Dequen-O’Byrne, Pascale
Abrams, Keith R.
Bujkiewicz, Sylwia
author_sort Jenkins, David A.
collection PubMed
description BACKGROUND: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. This study aims to investigate methods for the inclusion of RWE in NMA and its impact on the level of uncertainty around the effectiveness estimates, with particular interest in effectiveness of fingolimod. METHODS: A range of methods for inclusion of RWE in evidence synthesis were investigated by applying them to an illustrative example in relapsing remitting multiple sclerosis (RRMS). A literature search to identify RCTs and RWE evaluating treatments in RRMS was conducted. To assess the impact of inclusion of RWE on the effectiveness estimates, Bayesian hierarchical and adapted power prior models were applied. The effect of the inclusion of RWE was investigated by varying the degree of down weighting of this part of evidence by the use of a power prior. RESULTS: Whilst the inclusion of the RWE led to an increase in the level of uncertainty surrounding effect estimates in this example, this depended on the method of inclusion adopted for the RWE. ‘Power prior’ NMA model resulted in stable effect estimates for fingolimod yet increasing the width of the credible intervals with increasing weight given to RWE data. The hierarchical NMA models were effective in allowing for heterogeneity between study designs, however, this also increased the level of uncertainty. CONCLUSION: The ‘power prior’ method for the inclusion of RWE in NMAs indicates that the degree to which RWE is taken into account can have a significant impact on the overall level of uncertainty. The hierarchical modelling approach further allowed for accommodating differences between study types. Consequently, further work investigating both empirical evidence for biases associated with individual RWE studies and methods of elicitation from experts on the extent of such biases is warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01399-3.
format Online
Article
Text
id pubmed-8502389
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85023892021-10-20 Methods for the inclusion of real-world evidence in network meta-analysis Jenkins, David A. Hussein, Humaira Martina, Reynaldo Dequen-O’Byrne, Pascale Abrams, Keith R. Bujkiewicz, Sylwia BMC Med Res Methodol Research BACKGROUND: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. This study aims to investigate methods for the inclusion of RWE in NMA and its impact on the level of uncertainty around the effectiveness estimates, with particular interest in effectiveness of fingolimod. METHODS: A range of methods for inclusion of RWE in evidence synthesis were investigated by applying them to an illustrative example in relapsing remitting multiple sclerosis (RRMS). A literature search to identify RCTs and RWE evaluating treatments in RRMS was conducted. To assess the impact of inclusion of RWE on the effectiveness estimates, Bayesian hierarchical and adapted power prior models were applied. The effect of the inclusion of RWE was investigated by varying the degree of down weighting of this part of evidence by the use of a power prior. RESULTS: Whilst the inclusion of the RWE led to an increase in the level of uncertainty surrounding effect estimates in this example, this depended on the method of inclusion adopted for the RWE. ‘Power prior’ NMA model resulted in stable effect estimates for fingolimod yet increasing the width of the credible intervals with increasing weight given to RWE data. The hierarchical NMA models were effective in allowing for heterogeneity between study designs, however, this also increased the level of uncertainty. CONCLUSION: The ‘power prior’ method for the inclusion of RWE in NMAs indicates that the degree to which RWE is taken into account can have a significant impact on the overall level of uncertainty. The hierarchical modelling approach further allowed for accommodating differences between study types. Consequently, further work investigating both empirical evidence for biases associated with individual RWE studies and methods of elicitation from experts on the extent of such biases is warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01399-3. BioMed Central 2021-10-09 /pmc/articles/PMC8502389/ /pubmed/34627166 http://dx.doi.org/10.1186/s12874-021-01399-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Jenkins, David A.
Hussein, Humaira
Martina, Reynaldo
Dequen-O’Byrne, Pascale
Abrams, Keith R.
Bujkiewicz, Sylwia
Methods for the inclusion of real-world evidence in network meta-analysis
title Methods for the inclusion of real-world evidence in network meta-analysis
title_full Methods for the inclusion of real-world evidence in network meta-analysis
title_fullStr Methods for the inclusion of real-world evidence in network meta-analysis
title_full_unstemmed Methods for the inclusion of real-world evidence in network meta-analysis
title_short Methods for the inclusion of real-world evidence in network meta-analysis
title_sort methods for the inclusion of real-world evidence in network meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502389/
https://www.ncbi.nlm.nih.gov/pubmed/34627166
http://dx.doi.org/10.1186/s12874-021-01399-3
work_keys_str_mv AT jenkinsdavida methodsfortheinclusionofrealworldevidenceinnetworkmetaanalysis
AT husseinhumaira methodsfortheinclusionofrealworldevidenceinnetworkmetaanalysis
AT martinareynaldo methodsfortheinclusionofrealworldevidenceinnetworkmetaanalysis
AT dequenobyrnepascale methodsfortheinclusionofrealworldevidenceinnetworkmetaanalysis
AT abramskeithr methodsfortheinclusionofrealworldevidenceinnetworkmetaanalysis
AT bujkiewiczsylwia methodsfortheinclusionofrealworldevidenceinnetworkmetaanalysis